- GTx's (GTXI) Enobosarm drug for non-small cell lung cancer failed to meet its primary endpoints regarding lean body mass (LBM) and physical function in two Phase III studies.
- However, Enobosarm did demonstrate "significant quantitative advantage in LBM compared to placebos in both trials."
- GTx intends to hold talks with the FDA and EU regulators about the company's next steps. (PR)
GTx's Enobosarm fails in two late-stage trials
Aug 19 2013, 08:31 ET